Development PipelineBrentuximab vedotin

an investigational antibody–drug conjugate directed to CD30

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

ECHELON-3: Relapsed/refractory DLBCL (BV + lenalidomide and rituximab vs placebo + lenalidomide and rituximab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

CheckMate 744: Relapsed/refractory second-line Hodgkin lymphoma in AYA patients (BV + nivolumab)

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGN35-015: Frontline Hodgkin lymphoma or CD30+ PTCL in older patients with significant comorbidities

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGN35-027: Frontline early/advanced stage Hodgkin lymphoma (A + AVD with G-CSF primary prophylaxis or AN + AD)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGN35-032: Frontline PTCL with CD30-low and -negative expression (BV + CHP)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGN35-033: Metastatic solid tumors (NSCLC, melanoma, and H&N)

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

Program Resources

High-level synopsis of brentuximab vedotin and ongoing clinical trials

View/Download

Detailed information about brentuximab vedotin clinical trials

View in Interactive Pipeline